Physician profile
Toronsa M Simpson
NPI 1205355526
$8,101.99
in general payments reported to CMS, 2019-2025
26 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,065 · 2022: $1,870 · 2023: $3,214 · 2024: $1,445 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,404 · Food and Beverage: $2,255 · Education: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,403.50 |
| Food and Beverage | $2,255.35 |
| Education | $507.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,132.01 | 2021-2023 | Axonics, Bulkamid |
| Teleflex LLC | $1,256.59 | 2023-2024 | Urolift |
| Janssen Biotech, INC. | $1,036.29 | 2021-2025 | Erleada |
| Astellas Pharma US INC | $955.52 | 2021-2023 | |
| Myovant Sciences INC. | $764.29 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $389.76 | 2022-2025 | Provenge |
| Janssen Scientific Affairs, LLC | $332.40 | 2023-2025 | Erleada |
| Sumitomo Pharma America, INC. | $270.58 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $116.46 | 2021-2022 | |
| Blue Earth Diagnostics | $112.98 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $105.24 | 2021-2025 | Lynparza, Keytruda |
| Myriad Genetic Laboratories, INC. | $102.84 | 2021-2022 | |
| Pfizer INC. | $81.62 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $78.13 | 2022 | |
| Abbvie INC. | $72.53 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $55.08 | 2022 | |
| Antares Pharma, INC. | $49.33 | 2022 | |
| Boston Scientific Corporation | $37.24 | 2021-2023 | Advance Xp |
| Verity Pharmaceuticals INC. | $25.56 | 2023 | Trelstar |
| Tolmar Pharmaceuticals, INC. | $24.41 | 2022 | |
| Allergan, INC. | $23.58 | 2021 | |
| Endo Pharmaceuticals INC. | $20.48 | 2021 | |
| Medtronic, INC. | $16.31 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.17 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.71 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toronsa Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.